Xeris Biopharma Holdings, Inc. reported record financial results for the fourth quarter and full-year ended December 31, 2024. The company achieved a total revenue of $203 million for the full year 2024, driven by strong demand for Recorlev and Gvoke. This performance exceeded the previously announced guidance range of $198 million to $202 million.
For the fourth quarter of 2024, total revenue reached $60 million, contributing to the record annual performance. The company also ended 2024 with over $71 million in cash, cash equivalents, and short-term investments, having generated positive cash flow in the fourth quarter. The net loss for the fourth quarter was $0.03 per share.
Looking ahead, Xeris provided its initial full-year 2025 total revenue guidance, projecting a range of $255 million to $275 million. This guidance reflects the company's confidence in continuing its growth trajectory and advancing its pipeline, including the Phase 3-ready XP-8121 program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.